Tenpoint Therapeutics received U.S. FDA approval for Yuvezzi, the first dual‑agent ophthalmic drop for presbyopia combining carbachol and brimonidine. The company concurrently closed financing totaling up to $235 million (equity and a senior secured term loan) to support commercialization, according to MedCity News and BioWorld reports. Tenpoint positioned Yuvezzi as a differentiation versus single‑mechanism eye drops from incumbents, and the financing package includes $85 million in Series B preferred stock and $150 million in nondilutive debt. The approval and capital raise mark Tenpoint’s transition from clinical development into launch execution in a competitive ophthalmic market where payer access and physician uptake will determine commercial success.